Bayer signals cautious yet aggressive push into pharma acquisitions after five-year pause

Bayer's CEO Bill Anderson told investors on the first-quarter earnings call that the company is ready to re-enter the pharmaceutical merger-and-acquisition market after a five-year hiatus.

He emphasized that the approach will be "careful but aggressive," indicating a willingness to pursue targets while managing risk.

The shift follows a period in which Bayer focused on other priorities, and the renewed interest could reshape its drug pipeline and competitive position.

Analysts will watch for any concrete offers in the coming months as Bayer seeks to expand its portfolio.